{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T10:53:11Z","timestamp":1792666391137,"version":"4.5.0"},"reference-count":26,"publisher":"American Medical Association (AMA)","issue":"7","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Netw Open"],"abstract":"\n Importance<\/jats:title>\n A nonadjuvanted bivalent respiratory syncytial virus (RSV) prefusion F (RSVpreF [Pfizer]) protein subunit vaccine was newly approved and recommended for pregnant individuals at 32 0\/7 to 36 6\/7 weeks\u2019 gestation during the 2023 to 2024 RSV season; however, clinical vaccine data are lacking.<\/jats:p>\n <\/jats:sec>\n \n Objective<\/jats:title>\n To evaluate the association between prenatal RSV vaccination status and perinatal outcomes among patients who delivered during the vaccination season.<\/jats:p>\n <\/jats:sec>\n \n Design, Setting, and Participants<\/jats:title>\n This retrospective observational cohort study was conducted at 2 New York City hospitals within 1 health care system among patients who gave birth to singleton gestations at 32 weeks\u2019 gestation or later from September 22, 2023, to January 31, 2024.<\/jats:p>\n <\/jats:sec>\n \n Exposure<\/jats:title>\n Prenatal RSV vaccination with the RSVpreF vaccine captured from the health system\u2019s electronic health records.<\/jats:p>\n <\/jats:sec>\n \n Main Outcome and Measures<\/jats:title>\n The primary outcome is preterm birth (PTB), defined as less than 37 weeks\u2019 gestation. Secondary outcomes included hypertensive disorders of pregnancy (HDP), stillbirth, small-for\u2013gestational age birth weight, neonatal intensive care unit (NICU) admission, neonatal respiratory distress with NICU admission, neonatal jaundice or hyperbilirubinemia, neonatal hypoglycemia, and neonatal sepsis. Logistic regression models were used to estimate odds ratios (ORs), and multivariable logistic regression models and time-dependent covariate Cox regression models were performed.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n Of 2973 pregnant individuals (median [IQR] age, 34.9 [32.4-37.7] years), 1026 (34.5%) received prenatal RSVpreF vaccination. Fifteen patients inappropriately received the vaccine at 37 weeks\u2019 gestation or later and were included in the nonvaccinated group. During the study period, 60 patients who had evidence of prenatal vaccination (5.9%) experienced PTB vs 131 of those who did not (6.7%). Prenatal vaccination was not associated with an increased risk for PTB after adjusting for potential confounders (adjusted OR, 0.87; 95% CI, 0.62-1.20) and addressing immortal time bias (hazard ratio [HR], 0.93; 95% CI, 0.64-1.34). There were no significant differences in pregnancy and neonatal outcomes based on vaccination status in the logistic regression models, but an increased risk of HDP in the time-dependent model was seen (HR, 1.43; 95% CI, 1.16-1.77).<\/jats:p>\n <\/jats:sec>\n \n Conclusions and Relevance<\/jats:title>\n In this cohort study of pregnant individuals who delivered at 32 weeks\u2019 gestation or later, the RSVpreF vaccine was not associated with an increased risk of PTB and perinatal outcomes. These data support the safety of prenatal RSVpreF vaccination, but further investigation into the risk of HDP is warranted.<\/jats:p>\n <\/jats:sec>","DOI":"10.1001\/jamanetworkopen.2024.19268","type":"journal-article","created":{"date-parts":[[2024,7,8]],"date-time":"2024-07-08T11:01:30Z","timestamp":1720436490000},"page":"e2419268","source":"Crossref","is-referenced-by-count":84,"title":["Nonadjuvanted Bivalent Respiratory Syncytial Virus Vaccination and Perinatal Outcomes"],"prefix":"10.1001","volume":"7","author":[{"given":"Moeun","family":"Son","sequence":"first","affiliation":[{"name":"Division of Maternal-Fetal Medicine, Department of Obstetrics and Gynecology, Weill Cornell Medical College, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura E.","family":"Riley","sequence":"additional","affiliation":[{"name":"Division of Maternal-Fetal Medicine, Department of Obstetrics and Gynecology, Weill Cornell Medical College, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna P.","family":"Staniczenko","sequence":"additional","affiliation":[{"name":"Division of Maternal-Fetal Medicine, Department of Obstetrics and Gynecology, Weill Cornell Medical College, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia","family":"Cron","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology, Weill Cornell Medical College, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven","family":"Yen","sequence":"additional","affiliation":[{"name":"Department of Information Technologies & Services, Weill Cornell Medical College, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charlene","family":"Thomas","sequence":"additional","affiliation":[{"name":"Division of Biostatistics, Department of Population Health Sciences, Weill Cornell Medical College, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evan","family":"Sholle","sequence":"additional","affiliation":[{"name":"Department of Information Technologies & Services, Weill Cornell Medical College, New York, New York"},{"name":"Division of Health Informatics, Department of Population Health Sciences, Weill Cornell Medical College, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lauren M.","family":"Osborne","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology, Weill Cornell Medical College, New York, New York"},{"name":"Department of Psychiatry, Weill Cornell Medical College, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heather S.","family":"Lipkind","sequence":"additional","affiliation":[{"name":"Division of Maternal-Fetal Medicine, Department of Obstetrics and Gynecology, Weill Cornell Medical College, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","published-online":{"date-parts":[[2024,7,8]]},"reference":[{"issue":"6","key":"zoi240628r2","doi-asserted-by":"publisher","first-page":"1100","DOI":"10.1093\/infdis\/jiaa752","article-title":"Respiratory syncytial virus-associated hospitalization rates among US infants: a systematic review and meta-analysis.","volume":"225","author":"McLaughlin","year":"2022","journal-title":"J Infect Dis"},{"issue":"2","key":"zoi240628r3","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2022.0527","article-title":"Mortality associated with influenza and respiratory syncytial virus in the US, 1999-2018.","volume":"5","author":"Hansen","year":"2022","journal-title":"JAMA Netw Open"},{"issue":"16","key":"zoi240628r4","doi-asserted-by":"publisher","first-page":"1451","DOI":"10.1056\/NEJMoa2216480","article-title":"Bivalent prefusion F vaccine in pregnancy to prevent RSV illness in infants.","volume":"388","author":"Kampmann","year":"2023","journal-title":"N Engl J Med"},{"issue":"5","key":"zoi240628r5","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1056\/NEJMoa1913556","article-title":"Single-dose nirsevimab for prevention of RSV in preterm infants.","volume":"383","author":"Griffin","year":"2020","journal-title":"N Engl J Med"},{"issue":"9","key":"zoi240628r6","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1056\/NEJMoa2110275","article-title":"Nirsevimab for prevention of RSV in healthy late-preterm and term infants.","volume":"386","author":"Hammitt","year":"2022","journal-title":"N Engl J Med"},{"issue":"34","key":"zoi240628r7","doi-asserted-by":"publisher","first-page":"920","DOI":"10.15585\/mmwr.mm7234a4","article-title":"Use of nirsevimab for the prevention of respiratory syncytial virus disease among infants and young children: recommendations of the Advisory Committee on Immunization Practices\u2014United States, 2023.","volume":"72","author":"Jones","year":"2023","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"41","key":"zoi240628r9","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.15585\/mmwr.mm7241e1","article-title":"Use of the Pfizer respiratory syncytial virus vaccine during pregnancy for the prevention of respiratory syncytial virus-associated lower respiratory tract disease in infants: recommendations of the Advisory Committee on Immunization Practices\u2014United States, 2023.","volume":"72","author":"Fleming-Dutra","year":"2023","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"11","key":"zoi240628r10","doi-asserted-by":"publisher","first-page":"1009","DOI":"10.1056\/NEJMoa2305478","article-title":"RSV prefusion F protein-based maternal vaccine\u2014preterm birth and other outcomes.","volume":"390","author":"Dieussaert","year":"2024","journal-title":"N Engl J Med"},{"key":"zoi240628r12","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajog.2023.10.046","article-title":"Society for Maternal-Fetal Medicine Statement: clinical considerations for the prevention of respiratory syncytial virus disease in infants.","author":"Society for Maternal-Fetal Medicine","year":"2024","journal-title":"Am J Obstet Gynecol"},{"issue":"4","key":"zoi240628r14","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1093\/jamia\/ocab266","article-title":"An architecture for research computing in health to support clinical and translational investigators with electronic patient data.","volume":"29","author":"Campion","year":"2022","journal-title":"J Am Med Inform Assoc"},{"key":"zoi240628r15","doi-asserted-by":"publisher","first-page":"S154","DOI":"10.1093\/infdis\/jiac120","article-title":"Respiratory syncytial virus is the leading cause of United States infant hospitalizations, 2009-2019: a study of the National (Nationwide) Inpatient Sample.","volume":"226","author":"Suh","year":"2022","journal-title":"J Infect Dis"},{"issue":"51","key":"zoi240628r16","doi-asserted-by":"publisher","first-page":"7632","DOI":"10.1016\/j.vaccine.2023.11.009","article-title":"Maternal Tdap and influenza vaccination uptake 2017-2021 in the United States: implications for maternal RSV vaccine uptake in the future.","volume":"41","author":"Law","year":"2023","journal-title":"Vaccine"},{"issue":"2","key":"zoi240628r17","doi-asserted-by":"publisher","DOI":"10.21106\/ijma.V11.N2","article-title":"Factors impacting vaccine uptake during pregnancy: a retrospective analysis.","volume":"11","author":"Coleman","year":"2022","journal-title":"Int J MCH AIDS"},{"issue":"5","key":"zoi240628r18","doi-asserted-by":"publisher","first-page":"e150","DOI":"10.1097\/AOG.0000000000002046","article-title":"Committee Opinion No. 700: methods for estimating the due date.","volume":"129","year":"2017","journal-title":"Obstet Gynecol"},{"key":"zoi240628r20","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1186\/1471-2431-13-92","article-title":"Validating the weight gain of preterm infants between the reference growth curve of the fetus and the term infant.","volume":"13","author":"Fenton","year":"2013","journal-title":"BMC Pediatr"},{"key":"zoi240628r21","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1186\/1471-2431-13-59","article-title":"A systematic review and meta-analysis to revise the Fenton growth chart for preterm infants.","volume":"13","author":"Fenton","year":"2013","journal-title":"BMC Pediatr"},{"issue":"39","key":"zoi240628r23","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.15585\/mmwr.mm7239a4","article-title":"Influenza, Tdap, and COVID-19 vaccination coverage and hesitancy among pregnant women\u2014United States, April 2023.","volume":"72","author":"Razzaghi","year":"2023","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"3","key":"zoi240628r24","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1093\/aje\/kww043","article-title":"Risk of preterm or small-for-gestational-age birth after influenza vaccination during pregnancy: caveats when conducting retrospective observational studies.","volume":"184","author":"Vazquez-Benitez","year":"2016","journal-title":"Am J Epidemiol"},{"issue":"14","key":"zoi240628r25","doi-asserted-by":"publisher","first-page":"1882","DOI":"10.1016\/j.vaccine.2021.02.070","article-title":"Guidance for design and analysis of observational studies of fetal and newborn outcomes following COVID-19 vaccination during pregnancy.","volume":"39","author":"Fell","year":"2021","journal-title":"Vaccine"},{"issue":"7","key":"zoi240628r26","doi-asserted-by":"publisher","first-page":"686","DOI":"10.1001\/jama.2020.9151","article-title":"Immortal time bias in observational studies.","volume":"325","author":"Yadav","year":"2021","journal-title":"JAMA"},{"key":"zoi240628r1","unstructured":"US Centers for Disease Control and Prevention. RSV Surveillance and Research. Accessed January 11, 2024. https:\/\/www.cdc.gov\/rsv\/research\/index.html"},{"key":"zoi240628r8","unstructured":"CDC Emergency Preparedness and Response. Limited availability of nirsevimab in the United States\u2014interim CDC recommendations to protect infants from respiratory syncytial virus (RSV) during the 2023\u20132024 respiratory virus season. Accessed January 11, 2024. https:\/\/emergency.cdc.gov\/han\/2023\/han00499.asp"},{"key":"zoi240628r11","unstructured":"US Food and Drug Administration. ABRYSVO package insert. Accessed January 30, 2024. https:\/\/www.fda.gov\/media\/171482\/download?attachment"},{"key":"zoi240628r13","unstructured":"The American College of Obstetricians and Gynecologists. Maternal respiratory syncytial virus vaccination. Updated September 2023. Accessed January 30, 2024. https:\/\/www.acog.org\/clinical\/clinical-guidance\/practice-advisory\/articles\/2023\/09\/maternal-respiratory-syncytial-virus-vaccination"},{"key":"zoi240628r19","unstructured":"EQUATOR (Enhancing the QUAlity and Transparency Of health Research) Network. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE)Statement: guidelines for reporting observational studies. Accessed March 29, 2024. https:\/\/www.equator-network.org\/reporting-guidelines\/strobe\/"},{"key":"zoi240628r22","unstructured":"US Centers for Disease Control and Prevention. RSVVaxView. Accessed April 14, 2024. https:\/\/www.cdc.gov\/vaccines\/imz-managers\/coverage\/rsvvaxview\/index.html#:~:text=Pregnant%20Persons%20RSV%20Vaccination%20Coverage&text=Estimates%20of%20vaccination%20coverage%20are%20based%20on%20electronic%20health%20data,the%20RSV%20vaccine%20was%2012.1%25"}],"container-title":["JAMA Network Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/articlepdf\/2820865\/son_2024_oi_240628_1719580337.36761.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,8]],"date-time":"2024-07-08T11:01:34Z","timestamp":1720436494000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/fullarticle\/2820865"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,8]]},"references-count":26,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2024,7,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamanetworkopen.2024.19268","relation":{},"ISSN":["2574-3805"],"issn-type":[{"value":"2574-3805","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7,8]]}}}